Patents by Inventor Miles Trupp

Miles Trupp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Novel mediator of neurotransmitter and psychostimulant responses
    Publication number: 20070010444
    Abstract: The present invention provides polypeptides (termed “egl-28 polypeptides”) that modulate neurotransmitter- and psychostimulant-induced responses. The invention also provides methods of modulating such responses, as well as and anti-egl-28 antibodies. The invention encompasses related polynucleotides, vectors, host cells, production methods, and compositions. Moreover, the invention includes methods for prescreening or screening for test agents that modulate neurotransmitter and psychostimulant responses.
    Type: Application
    Filed: May 26, 2006
    Publication date: January 11, 2007
    Inventors: Miles Trupp, Steven McIntire
  • Glial cell line-derived neurotrophic factor receptors
    Publication number: 20040126819
    Abstract: Receptors for Glial Cell Line-Derived Neurotrophic Factor (GDNF), their cellular expression, isolation, biochemical characterization, and sequences are disclosed. c-RET is disclosed as one receptor for GDNF; additional novel receptors are also disclosed. The preparation of monoclonal antibodies directed against GDNF is also disclosed.
    Type: Application
    Filed: September 26, 2003
    Publication date: July 1, 2004
    Inventors: Carlos F. Ibanez, Miles Trupp, Mart Saarma, Hannu Sariola, Urmas Arumae, Petro Suvanto
  • Assays using glial cell line-derived neurotrophic factor receptors
    Patent number: 6696259
    Abstract: Receptors for Glial Cell Line-Derived Neurotrophic Factor (GDNF), their cellular expression, isolation, biochemical characterization, and sequences are disclosed. c-RET is disclosed as one receptor for GDNF; additional novel receptors are also disclosed. The preparation of monoclonal antibodies directed against GDNF is also disclosed.
    Type: Grant
    Filed: May 22, 1997
    Date of Patent: February 24, 2004
    Assignee: Licentia Ltd.
    Inventors: Carlos F. Ibanez, Miles Trupp, Mart Saarma, Hannu Sariola, Urmas Arumäe, Petro Suvanto